StockNews.AI
VRTX
StockNews.AI
165 days

Vertex Announces UK MHRA Approval of ALYFTREK® (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis

1. Vertex Pharmaceuticals receives UK approval for ALYFTREK®, a new CF treatment. 2. Approval targets cystic fibrosis patients aged 6 and older with specific mutations.

2m saved
Insight
Article

FAQ

Why Very Bullish?

The approval enhances VRTX's market position significantly, similar to past CF drug launches.

How important is it?

The approval could substantially increase VRTX’s market share in the CF space amidst existing competition.

Why Long Term?

This approval could lead to sustained revenue growth over years, as seen before.

Related Companies

ABBVGILD
LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals (Nasdaq: VRTX) announced today that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for ALYFTREK® (deutivacaftor/tezacaftor/vanzacaftor), a once-daily next-in-class triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator treatment for people living with cystic fibrosis (CF) ages 6 years and older who have at least one F508del mutation or another responsive muta.

Related News